You are very far off the mark for the wAMD trial. Results were off the charts for that type of study in top line numbers, degree of out performance and the fact that the control arm outperformed big time, so the top line should have been even greater. The subset analysis very clearly identified a large cohort that it will be a no brainer for first line treatment, that's not to say that the other subsets will also not benefit. The degree of outperformance allows a much higher probability for successful phase 3.
As to MC, go have a look at a current comparator at similar stage of development - Kodiak Sciences (KOD on Nasdaq) and check out their MC.
explain the market cap, page-11
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
81.5¢ |
Change
0.030(3.82%) |
Mkt cap ! $1.003B | |||
| Open | High | Low | Value | Volume |
| 78.5¢ | 82.5¢ | 78.5¢ | $1.203M | 1.499M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5772 | 81.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.5¢ | 844 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |